Exclusive: French startup’s gene therapy dramatically reduces urinary incontinence in spinal cord injury patientsnews2025-10-01T15:08:15+00:00October 1st, 2025|Endpoints News|
Ansa Biotechnologies closes $54.4M Series B to boost US DNA manufacturing news2025-10-01T12:00:10+00:00October 1st, 2025|Endpoints News|
Vertanical unpacks Phase 3 success for cannabis-based painkillernews2025-10-01T11:01:14+00:00October 1st, 2025|Endpoints News|
Merck makes the case for PAH drug Winrevair in patients with earlier diseasenews2025-09-30T15:04:43+00:00September 30th, 2025|Endpoints News|
Metsera’s new obesity data create side effect and efficacy questions for Pfizer to answernews2025-09-30T11:31:58+00:00September 30th, 2025|Endpoints News|
Opus says gene therapy for ultra-rare disease boosted vision in teensnews2025-09-30T11:00:13+00:00September 30th, 2025|Endpoints News|
Larimar’s update on Friedreich’s ataxia drug derailed by allergic reactionsnews2025-09-29T15:13:21+00:00September 29th, 2025|Endpoints News|
Enanta’s RSV treatment fails Phase 2b study, but positives seen in subgroupsnews2025-09-29T15:07:30+00:00September 29th, 2025|Endpoints News|
A pivotal miss in hidradenitis suppurativa leaves MoonLake adriftnews2025-09-29T11:14:29+00:00September 29th, 2025|Endpoints News|
